Researchers reported in the Lancet that post-menopausal women with a family history of breast cancer are at the risk of developing the disease by taking an anti-hormone drug called anastrozole.
Doctors at Queen Mary University in London found a reduction in risk of 53 percent among volunteers who took the drug for five years, compared to counterparts who took a harmless lookalike called a placebo.
Some Older Patients With Breast Cancer can Opt to Avoid Radiotherapy
Results of the PRIME 2 trial presented at the 2013 San Antonio Breast Cancer Symposium reveal that omission of radiotherapy is a reasonable option for women age 65 or older.
Advertisement
Anastrozole is not only more effective than the two standard drugs for preventing breast-cancer, tamoxifen and raloxifene, it also has fewer side effects, they added.
The study enrolled 3,864 post-menopausal women considered to have a high inherited risk of breast cancer.
They were deemed to be in this category if they had had two or more blood relatives with breast cancer, had a mother or sister who developed breast cancer before the age of 50 or had a mother or sister who had cancer in both breasts.
![Combined Therapy Connected to Reduced Recurrence in Women With Small, HER2+ Breast Cancers]( "Combined Therapy Connected to Reduced Recurrence in Women With Small, HER2+ Breast Cancers")
In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery
At the followup-point, five years after enrolment, 40 women in the anastrozole group had developed breast cancer compared to 85 women in the placebo group.
"This research is an exciting development in breast cancer prevention. We now know anastrozole should be the drug of choice when it comes to reducing the risk of breast cancer in post-menopausal women with a family history or other risk factors for the disease," said Jack Cuzick, head of the university's Centre for Cancer Prevention.
"This class of drugs is more effective than previous drugs such as tamoxifen and crucially, it has fewer side effects."
Side effects were rare, mostly comprising small increases in muscle aches and pains, and hot flashes, according to Cuzick.
"Our priority now is ensuring that as many women as possible can benefit from these new findings," he said.
Anastrozole, marketed under the brand name Arimidex, works by preventing the body from making the hormone oestrogen, a source for many breast cancers.
It has been used for more than 10 years to treat postmenopausal women diagnosed with so-called oestrogen receptor positive breast cancer.
In a press release, the British charity Cancer Research UK, which helped fund the research, said the study was a "landmark."
The next step was to determine which women benefited most from the drug, and which were likely to have the least side effects from taking it for a prolonged period, it said.
Cuzick added that the researchers intended to follow the volunteers for "at least 10 years, and hopefully much longer," to see whether the preventative effect was sustained, and to monitor for any change in side-effects.
The study was simultaneously presented on Thursday at a conference on breast cancer in San Antonio, Texas.
Source: AFP
They were deemed to be in this category if they had had two or more blood relatives with breast cancer, had a mother or sister who developed breast cancer before the age of 50 or had a mother or sister who had cancer in both breasts.
Combined Therapy Connected to Reduced Recurrence in Women With Small, HER2+ Breast Cancers
In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery
Advertisement
At the followup-point, five years after enrolment, 40 women in the anastrozole group had developed breast cancer compared to 85 women in the placebo group.
"This research is an exciting development in breast cancer prevention. We now know anastrozole should be the drug of choice when it comes to reducing the risk of breast cancer in post-menopausal women with a family history or other risk factors for the disease," said Jack Cuzick, head of the university's Centre for Cancer Prevention.
"This class of drugs is more effective than previous drugs such as tamoxifen and crucially, it has fewer side effects."
Side effects were rare, mostly comprising small increases in muscle aches and pains, and hot flashes, according to Cuzick.
"Our priority now is ensuring that as many women as possible can benefit from these new findings," he said.
Anastrozole, marketed under the brand name Arimidex, works by preventing the body from making the hormone oestrogen, a source for many breast cancers.
It has been used for more than 10 years to treat postmenopausal women diagnosed with so-called oestrogen receptor positive breast cancer.
In a press release, the British charity Cancer Research UK, which helped fund the research, said the study was a "landmark."
The next step was to determine which women benefited most from the drug, and which were likely to have the least side effects from taking it for a prolonged period, it said.
Cuzick added that the researchers intended to follow the volunteers for "at least 10 years, and hopefully much longer," to see whether the preventative effect was sustained, and to monitor for any change in side-effects.
The study was simultaneously presented on Thursday at a conference on breast cancer in San Antonio, Texas.
Source: AFP
Women With HER2-positive Breast Cancer Benefited With Chemotherapy and Trastuzumab
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy
Advertisement
 Exercise Protects Against Aggressive Breast Cancer in Black Women, Says StudyRegular vigorous exercise reduces the risk of aggressive breast cancer in black women, says study. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
New study sheds light on the intrinsic, yet often overlooked, role of sleep preparation as a hardwired survival strategy.
Microgravity-induced bone loss in space, can be reduced by systemic delivery of NELL-1, a protein required for bone growth and its maintenance.
Researchers establish connections between Alzheimer's-linked genetic alterations and the functioning of brain cells.
Team at NeuroRestore introduces a groundbreaking gene therapy that has effectively promoted nerve regrowth and reconnection, post spinal cord injury.
Scientists aim to pinpoint particular functional pathways affected by these bacteria that may have an impact on skeletal health.
